Business Context and Reporting Period
This Form 8-K reports on the 2019 Annual Meeting of Stockholders held by Tocagen Inc. on May 29, 2019. The filing details the voting results for director elections and the ratification of the independent registered public accounting firm. The record date for the meeting was April 4, 2019, with 23,270,962 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting outcomes rather than financial performance.
Material Changes and Voting Results
A total of 17,436,475 shares were present at the meeting, representing approximately 75% of outstanding shares. The material outcomes were:
- Proposal 1 (Election of Directors): Stockholders elected three Class II Directors to serve until the 2022 Annual Meeting.
- Franklin M. Berger: 5,365,864 votes for; 3,754,820 votes withheld.
- Lori Kunkel, M.D.: 7,720,648 votes for; 1,400,036 votes withheld.
- David Parkinson, M.D.: 4,999,706 votes for; 4,120,978 votes withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
- Votes For: 16,807,037
- Votes Against: 40,487
- Abstention: 588,951
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the submission of matters to a vote of security holders.
Important Facts for Investors to Verify
- Verify the tenure of the newly elected directors (Franklin M. Berger, Lori Kunkel, M.D., and David Parkinson, M.D.) through the 2022 Annual Meeting.
- Confirm the engagement of Ernst & Young LLP for the fiscal year ending December 31, 2019.
- Note the significant number of broker non-votes (8,315,791) recorded for the director election proposals.
- Review the company's financial statements in other filings (e.g., 10-K or 10-Q) as this 8-K contains no financial data.